Pascal Juillerat
University Hospital of Lausanne
15 Papers
148 Citations
Pascal Juillerat is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Inflammatory bowel disease & Infliximab. The author has an hindex of 9, co-authored 15 publications.
Chat about Author
Papers
Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Pascal Juillerat,Stephanie Christen-Zäch,François-Xavier Troillet,Suzanne Gallot-Lavallée,Renato G. Pannizzon,Pierre Michetti +5 more
TL;DR: It is demonstrated that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases and the literature on the effectiveness of this biological agent was reviewed.
48
Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study
Pascal Juillerat,Valérie Pittet,Jean-Luc Bulliard,Idris Guessous,Antonino A,Christian Mottet,Christian Felley,John-Paul Vader,Pierre Michetti +8 more
TL;DR: This study characterize the population-based prevalence of Crohn's Disease and Ulcerative Colitis in a defined population of Switzerland and gives support to an increase in IBD prevalence in Europe.
48
Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel—EPACT II
Christian Mottet,John-Paul Vader,Christian Felley,Florian Froehlich,J. J. Gonvers,Pascal Juillerat,Reinhold W. Stockbrügger,Erika Angelucci,Frank Seibold,Pierre Michetti,Valérie Pittet +10 more
TL;DR: Proton pump inhibitors, steroids, azathioprine/6-mercaptopurine and infliximab are appropriate for upper gastro-duodenal Crohn's disease; for stenosis, endoscopic balloon dilation is the first-line therapy, although surgery is also appropriate.
Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel — EPACT II
Christian Felley,John Paul Vader,Pascal Juillerat,Valérie Pittet,Colm O'Morain,Yves Panis,Boris Vucelić,J.-J. Gonvers,Christian Mottet,Florian Froehlich,Pierre Michetti +10 more
TL;DR: Antibiotics, azathioprine/6-mercaptopurine and conservative surgery are the mainstay of therapy for fistulizing Crohn's disease and infliximab is a therapeutic option in patients without prior response to immunosuppressant therapy.
Drug Safety in Crohn’s Disease Therapy
Pascal Juillerat,Valérie Pittet,Christian Felley,Christian Mottet,Florian Froehlich,John-Paul Vader,Jean-Jacques Gonvers,Pierre Michetti +7 more
TL;DR: The drugs described in this article include 5-ASA compounds, antibiotics, antibiotics (metronidazole, ciprofloxacin and rifaximin), corticosteroids (budesonide, prednisone and equivalents), thiopurines (azathioprine and 6-mercaptopurine), methotrexate, anti-tumor necrosis factor inhibitors (infliximab, adalimumab, certolizum
21